Amarin Corporation(US:AMRN)2026-03-02 22:31Product Approval and Market Expansion - VASCEPA was first approved by the U.S. FDA in July 2012 for severe hypertriglyceridemia and received a label expansion in December 2019 for reducing cardiovascular risk in high-risk patients [455]. - The company has received marketing authorization for VAZKEPA in the EU, England, Wales, and Scotland in 2021, with various reimbursement approvals across multiple countries [465][468]. - The Recordati Licensing Agreement allows Recordati to commercialize VAZKEPA in 59 countries, with the potential for future product reimbursements and approvals [466]. - The company has filed for regulatory review in 22 countries and regions, receiving approval in 17 countries outside of the U.S. and EMA [471]. - VAZKEPA has been launched in several European countries, with national reimbursement secured in Sweden, England, and Spain among others [468]. - The company has established partnerships with seven commercial partners for VASCEPA and VAZKEPA, focusing on regulatory approval and commercialization [457]. - The company anticipates that the success of reimbursement negotiations will significantly impact the commercial opportunity of VAZKEPA in Europe [467]. - A patent issued in April 2024 extends VAZKEPA's market exclusivity to 2039, providing a competitive advantage in the European market [470]. - VASCEPA is under registration in additional countries in the MENA region, Israel, and ASEAN, with revenue from Israel recorded within European revenue [472]. Financial Performance - Total revenue, net decreased by $15.0 million, or 7%, to $213.6 million in 2025 from $228.6 million in 2024 [507]. - Product revenue, net fell by $21.8 million, or 11%, to $182.8 million in 2025, primarily due to an 8% decrease in VASCEPA sales in the U.S. [508]. - U.S. product revenue, net was $154.1 million in 2025, down from $166.7 million in 2024, attributed to a decline in net selling price due to generic competition [509]. - Licensing and royalty revenue increased by $6.9 million, or 29%, to $30.9 million in 2025, driven by a $25.0 million upfront payment from the Recordati Licensing Agreement [513]. - Cost of goods sold decreased by $54.5 million, or 37%, to $92.8 million in 2025, reflecting cost management and supplier agreement amendments [515]. - Overall gross margin on product sales improved to 49% in 2025 from 28% in 2024, with a gross margin of 49% excluding restructuring inventory charges [517]. - Product revenue from Europe increased to $18.4 million in 2025 from $13.7 million in 2024, primarily from the UK and Spain [511]. - Revenue from collaboration partners in the Rest of the World (RoW) decreased to $10.2 million in 2025 from $24.2 million in 2024, reflecting variability in early-stage market development [512]. Expenses and Cost Management - Selling, general and administrative expenses decreased by $37.3 million, or 24%, from $152.3 million in 2024 to $115.0 million in 2025 [518]. - Research and development expenses decreased by $1.1 million, or 5%, from $20.9 million in 2024 to $19.8 million in 2025 [519]. - Restructuring expenses increased by $36.2 million, or 100%, due to the Global Restructuring Plan associated with the Recordati Licensing Agreement [520]. - The Global Restructuring Plan is expected to reduce operating costs by approximately $70 million annually through the elimination of commercial roles in European operations [474]. Cash Flow and Investments - Cash and cash equivalents and short-term investments totaled $302.8 million as of December 31, 2025 [525]. - Net cash provided by operating activities was $6.7 million in 2025, compared to a net cash used of $31.0 million in 2024 [526]. - Interest income, net, decreased by $2.6 million, or 19%, from $13.4 million in 2024 to $10.8 million in 2025 [521]. - Other income, net, increased from $1.2 million in 2024 to $3.3 million in 2025 [522]. - Provision for income taxes decreased by $2.2 million, or 44%, from $5.0 million in 2024 to $2.8 million in 2025 [523]. Research and Clinical Studies - The REDUCE-IT study has been pivotal for VASCEPA, with over 35,000 patient years of study experience, leading to additional indicated uses being pursued globally [475]. - More than 70 global medical societies have recognized the use of icosapent ethyl (IPE) for cardiovascular risk reduction, with significant findings from the REDUCE-IT study showing a 25% reduction in major cardiovascular events [476].